Fate Therapeutics, Inc. (FATE)
2.11
+0.02
(+0.96%)
USD |
NASDAQ |
Oct 23, 16:00
2.11
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Net Income (Quarterly) : -30.16M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -30.16M |
| March 31, 2026 | -31.21M |
| December 31, 2025 | -32.37M |
| September 30, 2025 | -32.25M |
| June 30, 2025 | -34.07M |
| March 31, 2025 | -37.62M |
| December 31, 2024 | -52.15M |
| September 30, 2024 | -47.68M |
| June 30, 2024 | -38.43M |
| March 31, 2024 | -48.00M |
| December 31, 2023 | -44.12M |
| September 30, 2023 | -45.17M |
| June 30, 2023 | -52.76M |
| March 31, 2023 | -18.88M |
| December 31, 2022 | -56.36M |
| September 30, 2022 | -83.56M |
| June 30, 2022 | -76.10M |
| March 31, 2022 | -65.69M |
| December 31, 2021 | -68.62M |
| September 30, 2021 | -43.31M |
| June 30, 2021 | -55.13M |
| March 31, 2021 | -45.09M |
| December 31, 2020 | -53.11M |
| September 30, 2020 | -58.68M |
| June 30, 2020 | -28.07M |
| Date | Value |
|---|---|
| March 31, 2020 | -33.52M |
| December 31, 2019 | -28.30M |
| September 30, 2019 | -26.61M |
| June 30, 2019 | -23.48M |
| March 31, 2019 | -19.76M |
| December 31, 2018 | -16.03M |
| September 30, 2018 | -16.78M |
| June 30, 2018 | -19.65M |
| March 31, 2018 | -14.14M |
| December 31, 2017 | -12.50M |
| September 30, 2017 | -10.68M |
| June 30, 2017 | -9.645M |
| March 31, 2017 | -10.13M |
| December 31, 2016 | -7.94M |
| September 30, 2016 | -8.737M |
| June 30, 2016 | -8.408M |
| March 31, 2016 | -8.377M |
| December 31, 2015 | -7.446M |
| September 30, 2015 | -6.886M |
| June 30, 2015 | -7.779M |
| March 31, 2015 | -7.881M |
| December 31, 2014 | -6.233M |
| September 30, 2014 | -6.603M |
| June 30, 2014 | -6.067M |
| March 31, 2014 | -6.98M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 2.082M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.2505 |
| Enterprise Value | 168.13M |
| Gross Profit Margin (Quarterly) | -33.53% |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -49.91% |
| Normalized Earnings Yield | -49.73 |